Cocrystal Pharma (COCP) Cash & Equivalents (2010 - 2026)

Cocrystal Pharma (COCP) has 17 years of Cash & Equivalents data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 31.96% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 31.96% YoY), and the FY2025 full-year result was $7.1 million, down 28.54% from the prior year.
• Cash & Equivalents eased to $4.8 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $54.8 million in Q1 2022 to a low of $75000.0 in Q2 2022.
• A 5-year average of $16.2 million and a median of $9.9 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 99.89% in 2022 and surged 43125.33% in 2023, its largest moves.
• Tracing COCP's Cash & Equivalents over 5 years: stood at $37.2 million in 2022, then fell by 28.99% to $26.4 million in 2023, then slumped by 62.41% to $9.9 million in 2024, then decreased by 28.54% to $7.1 million in 2025, then sank by 32.96% to $4.8 million in 2026.
• Business Quant data shows COCP's Cash & Equivalents at $4.8 million in Q1 2026, $7.1 million in Q4 2025, and $7.8 million in Q3 2025.